The earnings call highlights strategic advancements and a strong financial partnership with Incyte, positioning Prelude well for future development. However, challenges remain in differentiating their products in competitive spaces and ensuring timely clinical progress.

Company Guidance

During the Prelude Therapeutics Investor Conference Call, the company provided guidance on its strategic focus and future clinical development activities. Prelude is set to advance two key development candidates into clinical trials by 2026: a JAK2V617F selective inhibitor for myeloproliferative neoplasms (MPN) and a KAT6A selective degrader for ER-positive breast cancer. The JAK2V617F inhibitor targets a mutation present in over 95% of polycythemia vera patients and 50-60% of patients with myelofibrosis and essential thrombocythemia, representing a market of over 200,000 MPN patients in the U.S. alone. The KAT6A program aims to address resistance in ER-positive breast cancer, with preclinical data suggesting a differentiated safety and efficacy profile over existing treatments. Prelude announced a significant $910 million deal with Incyte, including an upfront payment of $60 million, providing a financial runway into 2027, and plans to file an Investigational New Drug (IND) application for the JAK2 program in early 2026.

Strategic Decisions and Financial Position

Prelude Therapeutics has made strategic decisions to focus on R&D, optimize capital allocation, and align business strategy with high-probability success programs. These efforts have strengthened their financial position, providing additional cash runway into 2027.

Advancement of Development Candidates

Prelude is advancing two development candidates into clinical development by 2026: a JAK2V617F selective inhibitor for myeloproliferative neoplasms and a KAT6A selective degrader for ER-positive breast cancer.

Incyte Collaboration

Prelude entered into an exclusive option agreement with Incyte for the JAK2V617F program, potentially bringing up to $910 million in cash payments and future milestones, including a $35 million upfront fee and $25 million stock purchase.

Discovery Progress

Significant progress in next-generation ADCs called degrader antibody conjugates (DACs), with potential for licensing agreements to bring in non-dilutive capital.

Prelude Therapeutics (PRLD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PRLD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 18, 2026	2025 (Q4)	-0.13 / -	-0.37	―	―	―
Nov 12, 2025	2025 (Q3)	-0.37 / -0.26	-0.43	39.53% (+0.17)	―
Aug 14, 2025	2025 (Q2)	-0.44 / -0.41	-0.46	10.87% (+0.05)	―	―
May 06, 2025	2025 (Q1)	-0.47 / -0.42	-0.42	0.00% (0.00)	―	―
Mar 10, 2025	2024 (Q4)	-0.46 / -0.37	-0.45	17.78% (+0.08)	―	―
Nov 06, 2024	2024 (Q3)	-0.47 / -0.43	-0.45	4.44% (+0.02)	―	―
Aug 12, 2024	2024 (Q2)	-0.43 / -0.46	-0.54	14.81% (+0.08)	―	―
May 07, 2024	2024 (Q1)	-0.48 / -0.42	-0.58	27.59% (+0.16)	―	―
Feb 15, 2024	2023 (Q4)	-0.49 / -0.45	-0.6	25.00% (+0.15)	―	―
Nov 01, 2023	2023 (Q3)	-0.58 / -0.45	-0.63	28.57% (+0.18)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PRLD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 12, 2025	$1.35	$1.47	+8.89%
Aug 14, 2025	$0.91	$0.94	+3.30%
May 06, 2025	$0.80	$0.76	-5.00%
Mar 10, 2025	$0.74	$0.67	-9.46%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Prelude Therapeutics (PRLD) report earnings?

Prelude Therapeutics (PRLD) is schdueled to report earning on Mar 18, 2026, Before Open (Confirmed).

What is Prelude Therapeutics (PRLD) earnings time?

Prelude Therapeutics (PRLD) earnings time is at Mar 18, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PRLD EPS forecast?

PRLD EPS forecast for the fiscal quarter 2025 (Q4) is -0.13.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing